FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Friday

 

NIH Grant to Advance MS Therapy Targeting Remyelination





























Novoron Bioscience will use award in proof-of-concept study of NOVO-117, a RhoA inhibitor, in repairing myelin damage

Novoron Bioscience, Inc., a biotech company focused on developing therapies for disorders of the central nervous system, recently announced that it has received a $680,000 National Institutes of Health (NIH) grant to assess the potential of a new therapeutic approach to induce remyelination in multiple sclerosis (MS).
MS is an autoimmune disease where the body’s own immune system attacks the protective coat around nerves in the brain and spinal cord, known as myelin. The destruction of myelin (demyelination) is irreversible in MS, and it disrupts signal transmission between nerves, leading to impairments in movement, vision, and speech. Demyelination is the primary cause of disability and death in MS patients.

Novoron received six NIH grants (totaling more than $1.2 million) to investigate novel therapeutic strategies for the treatment of several neurological disorders, namely MS, spinal cord injury, and stroke. The latest grant was awarded under the NIH’s Small Business Innovation Research (SBIR) Program.

For MS, the company will assess a therapeutic approach based on remyelination.

“These NIH grants are invaluable in helping us advance our novel therapeutic approaches, addressing fundamental limitations in the treatment of disorders of the central nervous system such as multiple sclerosis, spinal cord injury and optic neuropathies,” said Dr. Travis Stiles, president and CEO of Novoron Bioscience, in a press release. “We look forward to the opportunity to continue to extend our unique technological approach to CNS [central nervous system] disease and assess our capacity to promote remyelination and preserve neuronal viability in multiple sclerosis.”

Oligodendrocytes are the cells responsible for producing myelin, and when these cells die, due to trauma or environmental factors such as toxicity, the myelin sheath may become degraded. Normally, oligodendrocyte precursor cells (OPCs) infiltrate the damaged area and take over the function of oligodendrocytes, synthesizing new myelin and repairing the damage. However, in MS, a persistent myelin loss together with inflammation (due to immune infiltrates) inhibit the OPCs’ ability to produce new myelin. Such inhibition is the result of an unwanted activation of a molecule called RhoA. Novoron’s therapeutic lead compound, NOVO-117, targets RhoA by acting on a previously unknown mediator of RhoA activation — LRP1 (low density lipoprotein-related protein 1).

“Today’s approved therapies are aimed solely at dampening the autoimmune attack on myelin, but there are currently no approved treatments to repair damage after an attack has occurred,” explained Dr. Stiles. “Our approach shows substantial promise towards repairing this damage, a process known as remyelination, which not only protects neurons from further damage, but can lead to recovery of cell function and prevention of death.”

“Rho and Rho-kinase are well considered targets for multiple sclerosis, but are difficult to effectively inhibit therapeutically in the brain. Novoron’s technological foundation relies on our unique approach to targeting RhoA in a fashion that is amenable to disorders of the brain and spinal cord,” concluded Dr. Stiles.

The NIH grant will allow the development of a proof-of-concept study to validate further preclinical studies on NOVO-117 as a therapy for MS.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length


Go to Newer News Go to Older News